Schwartz GK - Search Results

1

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L, Klimstra DS, Fridman D, Kelsen DP, Saltz LB. Chung KY, et al. Among authors: schwartz gk, schwartz l. J Clin Oncol. 2005 Mar 20;23(9):1803-10. doi: 10.1200/JCO.2005.08.037. Epub 2005 Jan 27. J Clin Oncol. 2005. PMID: 15677699

2

Phase II trial of fazarabine (arabinofuranosyl-5-azacytidine) in patients with advanced pancreatic adenocarcinoma.

Casper ES, Schwartz GK, Kelsen DP. Casper ES, et al. Among authors: schwartz gk. Invest New Drugs. 1992 Aug;10(3):205-9. doi: 10.1007/BF00877247. Invest New Drugs. 1992. PMID: 1385354 Clinical Trial.

3

Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma.

Casper ES, Schwartz GK, Johnson B, Kelsen DP. Casper ES, et al. Among authors: schwartz gk. Invest New Drugs. 1992 Nov;10(4):313-6. doi: 10.1007/BF00944187. Invest New Drugs. 1992. PMID: 1487406 Clinical Trial.

4

Potentiation of apoptosis by treatment with the protein kinase C-specific inhibitor safingol in mitomycin C-treated gastric cancer cells.

Schwartz GK, Haimovitz-Friedman A, Dhupar SK, Ehleiter D, Maslak P, Lai L, Loganzo F Jr, Kelsen DP, Fuks Z, Albino AP. Schwartz GK, et al. J Natl Cancer Inst. 1995 Sep 20;87(18):1394-9. doi: 10.1093/jnci/87.18.1394. J Natl Cancer Inst. 1995. PMID: 7658500

5

The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents.

Nabeya Y, Loganzo F Jr, Maslak P, Lai L, de Oliveira AR, Schwartz GK, Blundell ML, Altorki NK, Kelsen DP, Albino AP. Nabeya Y, et al. Among authors: schwartz gk. Int J Cancer. 1995 Feb 20;64(1):37-46. doi: 10.1002/ijc.2910640109. Int J Cancer. 1995. PMID: 7665247

6

Granulocyte colony-stimulating factor: effective in ameliorating fluorouracil-based myelosuppression?

Christman K, Saltz L, Schwartz G, Friedrich C, Kelsen D. Christman K, et al. J Natl Cancer Inst. 1993 May 19;85(10):826-7. doi: 10.1093/jnci/85.10.826. J Natl Cancer Inst. 1993. PMID: 7683729 Clinical Trial. No abstract available.

7

A phase II trial of alpha-interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors.

Saltz L, Kemeny N, Schwartz G, Kelsen D. Saltz L, et al. Cancer. 1994 Aug 1;74(3):958-61. doi: 10.1002/1097-0142(19940801)74:3<958::aid-cncr2820740326>3.0.co;2-x. Cancer. 1994. PMID: 8039124 Clinical Trial.

8

Defining the invasive phenotype of proximal gastric cancer cells.

Schwartz GK, Wang H, Lampen N, Altorki N, Kelsen D, Albino AP. Schwartz GK, et al. Cancer. 1994 Jan 1;73(1):22-7. doi: 10.1002/1097-0142(19940101)73:1<22::aid-cncr2820730106>3.0.co;2-o. Cancer. 1994. PMID: 8275429

9

Characterization of cell lines established from human gastric-esophageal adenocarcinomas. Biologic phenotype and invasion potential.

Altorki N, Schwartz GK, Blundell M, Davis BM, Kelsen DP, Albino AP. Altorki N, et al. Among authors: schwartz gk. Cancer. 1993 Aug 1;72(3):649-57. doi: 10.1002/1097-0142(19930801)72:3<649::aid-cncr2820720305>3.0.co;2-l. Cancer. 1993. PMID: 8334620

10

Protein kinase C: a novel target for inhibiting gastric cancer cell invasion.

Schwartz GK, Jiang J, Kelsen D, Albino AP. Schwartz GK, et al. J Natl Cancer Inst. 1993 Mar 3;85(5):402-7. doi: 10.1093/jnci/85.5.402. J Natl Cancer Inst. 1993. PMID: 8433394

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

325 results

Search Page

Filters